OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors
OCTIMET Oncology NV (OCTIMET) has secured EUR 11.3 million in a Series A investment round, enabling the company to accelerate the development of a clinically de-risked MET kinase inhibitor, as single agent or in combination with standard of care and targeted agents for the treatment of solid cancers.
2 Bridge is attending BIO-Europe Spring
Our colleagues Ann Meulemans and Geertje Van Beeck are attending the 11th edition of BIO-Europe Spring, the annual international life science partnering conference, in Barcelona, from March 20-22th, 2017.
Our CMC Newsletter
The amount of new legislations and guidelines to control drug products in the last 2 years, has put a lot of strain on quality departments within pharmaceutical organizations.
Are you struggling to comply with these new guidelines? Let us help you….
2 Bridge has a team of people with the right experience to help you with both strategic and hands-on support to guide you to compliance with these recent guidelines.
We can offer senior staff or junior staff to support your every need on your way to compliance….
We have moved!
We are excited to announce that 2 Bridge has officially moved from its former office in Turnhout to a new address: Rodendijk 60X 2980 Zoersel Come visit us at our new location!
2 Bridge is attending BIO-Europe 2016
Our colleagues Ann Meulemans and Leen Thielemans are attending Europe’s largest partnering conference serving the global biotechnology industry, BIO-Europe 2016, in November, 2016.
Strategic collaboration between 2 Bridge and Inovigate
2 Bridge and Inovigate are proud to announce a strategic collaboration to provide fully integrated solutions in healthcare product development. The combined strength of our services go from drug development strategy over due diligence and opportunity scouting to product development, strategy and business planning – Matching the Target Product Profile with the Target Market Profile.
2 Bridge going global with Start2Export2Canada
In the context of international business development and expansion, 2 Bridge and Denys Research Consultants (DRC) are participating in Start2Export2Canada, an international trade mission to Canada.
This business trip to Montreal-Drummondville-Quebec is part of a coaching programme organized by Flanders Investment and Trade and VOKA, coaching entrepeneurs on how to establish business on the Canadian market.
Strategic collaboration between 2 Bridge and Denys Research Consultants
2 Bridge and Denys Research Consultants are proud to announce a strategic collaboration to provide fully integrated solutions in clinical and healthcare product development. The combined strength of our services go from drug development strategy over due diligence and opportunity scouting to full clinical trial services in project management and monitoring for Phase I through Phase IV clinical trials. Our customer portfolio ranges from the academic research over small and medium-sized biotech and medical device companies to large pharmaceutical enterprises.
2 Bridge is attending the Cell & Gene Therapy Manufacturing Conference
Our colleague Geertje Van Beeck (Managing Partner) is attending Europe’s most comprehensive advanced therapies manufacturing conference, the Cell & Gene Therapy Manufacturing Conference in London, on Sept 7-8, 2016.
2 Bridge is attending the Vlerick Healthcare Conference
Our colleagues Ann Meulemans (CEO & Managing Partner) and Leen Thielemans (Managing Partner) are attending the Vlerick Healthcare Conference in Brussels on Oct 27, 2016.